Loading

Cannabis Caucus

  • by Justin Strekal, NORML Political Director September 18, 2017

    First off – a huge thank you to all of those activists and chapter leads from around the country who came to DC to participate in our National Conference and Lobby Day.

    By the numbers:

    –     140+ attendees
    –     21 speakers
    –     5 members of Congress
    –     150+ congressional meetings
    –     1 goal: End marijuana prohibition.

    More to come as we follow up with our attendees and continue to build on the momentum generated (and have our photographer send us the rest of the pictures!).

    Congresswoman Eleanor Holmes Norton (D-DC), Maryland State Senator Richard Madaleno, and aide to Virginia State Senator Dave Marsden receive awards from the DMV NORML Coalition

    Congresswoman Eleanor Holmes Norton (D-DC), Maryland State Senator Richard Madaleno, and aide to Virginia State Senator Dave Marsden receive awards from the DMV NORML Coalition

    Congressman Dana Rohrabacher (R-CA) addresses NORML citizens before they depart to their congressional meetings

    Congressman Dana Rohrabacher (R-CA) addresses NORML citizens before they depart to their congressional meetings

    Senator Cory Booker (D-NJ) met with NORML chapter leaders from around the country to discuss his legislation known as The Marijuana Justice Act

    Senator Cory Booker (D-NJ) met with NORML chapter leaders from around the country to discuss his legislation known as The Marijuana Justice Act

    Some of the feedback from the lobby day we received:

    Mikel Weisser, Executive Director of Arizona NORML in a meeting with Senator Flake’s staffer, reported “She [Katie] is familiar with Endocannabinoid Receptor System. It is one of her policy issue areas. She said she did not know if the Senator was aware of the E.R.S., so I wrote a short note on [the] materials and she said she would show him.”

    In a meeting with Senator Casey’s staffer, Les Stark, head of the Keystone Cannabis Coalition reported “They are open to the issue but do not seem very bold. They don’t want to set too far ahead of the Pennsylvania legislature…we intend to follow-up.”

    Jane Preece, in a meeting with Senator Harris’s staffer, reported “Ms. Hira is smart and is interested in the recent research showing pot is safe and effective.”

    00057959

  • by Justin Strekal, NORML Political Director September 11, 2017

    3410000930_95fc2866fa_zIn a quick deal between President Trump and Congress, a three-month budget continuing resolution will be in effect until December 8, 2017, maintaining current spending levels.

    While this seems mundane (it is), it is important for marijuana policy because it guarantees a temporary extension of the Rohrabacher-Blumenauer protections for lawful medical marijuana programs from Attorney General Jeff Sessions.

    In context, this comes on the heels of the House Rules Committee, led by prohibitionist Representative Pete Sessions (R-TX), blocking multiple amendments related to marijuana from receiving consideration by the full House earlier this week, thus ending their consideration for the 2018 House CJS Appropriates bill.

    Amendments included: ending the federal incentive to revoke drivers licenses from those charged with marijuana offenses; protections for states that have implemented hemp programs; a reduction in funding for the DEA’s cannabis eradication program; expanded access to researchersprotections for banks to provide services to marijuana businesses; allowing the District of Columbia to implement adult-use sales, and expanded protections to the eight states that have outright legalized marijuana.

    Most notably, Chairman Pete Sessions also blocked the amendment offered by Representatives Dana RohrabacherEarl Blumenauer, and other allies in the House This language has been included in budgets since 2014, with language maintains that federal funds cannot be used to prevent states from “implementing their own state laws that authorize the use, distribution, possession or cultivation of medical marijuana.”

    Eariler this year, Senator Patrick Leahy (D-VT) successfully offered and passed the Rohrabacher-Blumenauer amendment in the Senate Appropriations Committee, meaning that the language will be considered in a conference committee regardless of the fact that the full House was denied the opportunity to express it’s support for the 30 states which have legalized medical marijuana and 16 states that have authorized CBD oil access.

    The fight is still to come, and you can send a message to your elected officials about the need to include this in the budget process here by clicking here. 

     

  • by Justin Strekal, NORML Political Director September 7, 2017

    FBScorecardLate Wednesday night, the House Rules Committee led by prohibitionist Representative Pete Sessions (R-TX) blocked multiple amendments related to marijuana from receiving consideration by the full House, thus ending their consideration and silencing the ability for the lower chamber to offer protections from Attorney General Jeff Sessions when it comes to cannabis.

    Amendments included: ending the federal incentive to revoke drivers licenses from those charged with marijuana offenses; protections for states that have implemented hemp programs; a reduction in funding for the DEA’s cannabis eradication program; expanded access to researchersprotections for banks to provide services to marijuana businesses; allowing the District of Columbia to implement adult-use sales, and expanded protections to the eight states that have outright legalized marijuana.

    Most notably, the amendment offered by Representatives Dana RohrabacherEarl Blumenauer, and other allies in the House had again offered the Rohrabacher-Blumenauer amendment to continue to protect lawful state medical marijuana programs from the federal government. Specifically, the language maintains that federal funds cannot be used to prevent states from “implementing their own state laws that authorize the use, distribution, possession or cultivation of medical marijuana.”

    Representatives Blumenauer and Rohrabacher released the following statement in response:

    “By blocking our amendment, Committee leadership is putting at risk the millions of patients who rely on medical marijuana for treatment, as well as the clinics and businesses that support them. This decision goes against the will of the American people, who overwhelmingly oppose federal interference with state marijuana laws. These critical protections are supported by a majority of our colleagues on both sides of the aisle. There’s no question: If a vote were allowed, our amendment would pass on the House floor, as it has several times before.

    “Our fight to protect medical marijuana patients is far from over. The marijuana reform movement is large and growing. This bad decision by the House Rules Committee is an affront to the 46 states and the District of Columbia that have legalized use and distribution of some form of medical marijuana. These programs serve millions of Americans. This setback, however, is not the final word. As House and Senate leadership negotiate a long-term funding bill, we will fight to maintain current protections.”

    Since 2014, members of Congress have passed annual spending bills that have included the Rohrabacher-Blumenauer language, protecting those who engage in the state-sanctioned use and dispensing of medical cannabis from undue prosecution by the Department of Justice.

    Most recently, the amendment was reauthorized by Congress in May as part of a short term spending package, in spite of US Attorney General Jeff Sessions aggressively lobbying Congressional leadership to ignore the provisions. At the time of the signing of the bill, President Trump issued a signing statement objecting to the Rohrbacher-Blumenauer provision.

    Without these maintained protections, it is difficult to assess how much business confidence and investment will continue to pour into the nascent industry, which currently serves over 3 million

    However as the Congressmen indicated in their statement, the fight is not over. In July, Senator Patrick Leahy (D-VT) successfully offered and passed the Rohrabacher-Blumenauer amendment in the Senate Appropriations Committee, meaning that the language will be considered in a conference committee despite the fact that the House was denied the opportunity to express it’s support for the 30 states which have legalized medical marijuana and 16 states that have authorized CBD oil access.

    We will continue to advocate for the members who will be in the conference committee to maintain the language from the Senate version in order to continue to serve the millions of men, women, and children who depend on their medication. On Monday and Tuesday, September 11th and 12th, NORML will hold it’s annual Conference and Lobby Day in DC and will focus on the need to not allow our progress to be rolled back – if you can join us in DC, click here to register.

    Keep fighting with us – send a message to your federal elected officials now. 

  • by NORML August 16, 2017

    mj_researchRepresentatives Andy Harris, M.D. (R-MD-01), Earl Blumenauer (D-OR-03), H. Morgan Griffith (R-VA-09), and Zoe Lofgren (D-CA-19) introduced H.R. 3391: The Medical Marijuana Research Act of 2017.

    This Act amends the federal law to facilitate clinical investigations involving the use of cannabis and cannabis-derived products.

    As you may know, there are many benefits to medical cannabis. Those suffering from PTSD, Tourette’s Syndrome, Parkinson’s Disease, and many other debilitating conditions have found relief because of medical marijuana.  

    But, despite the fact that over 200 million Americans now have legal access to some form of medical marijuana, present regulations make clinical investigations involving cannabis needlessly onerous. Passage of this measure would expedite federal reviews of clinical protocols, provide greater access to scientists who wish to study the drug, and mandate an FDA review of the relevant science.

    Please click HERE to contact your Representative and urge him/her to support this important measure.

     

  • by Justin Strekal, NORML Political Director July 19, 2017

    Yesterday, NORML moderated a Facebook Congressional Conversation on marijuana law reform with Representatives Earl Blumenauer, Tom Garrett, Beto O’Rourke, and Justin Amash.

    We discussed a wide range of issues including the needless burden of the federal driver’s license suspension mandate, access to medical marijuana, racial injustice, and pending bipartisan legislation to remove cannabis from the Controlled Substances Act.

    WATCH NOW:

    Share on Facebook  |  Share on Twitter

    The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color. Only when lawmakers speak honestly about the effects of prohibition and the senseless burdens it imposes on our communities will we be able to win substantial reform.

    “At a time when 29 states and the District of Columbia have made the decision to regulate the sale and use of marijuana, we should rethink how the federal government approaches this drug. Our current approach to marijuana prevents legitimate medical use, fills our prisons with nonviolent offenders and continues to fuel drug violence,” said Representative Beto O’Rourke in a statement promoting the event.

    In our continued effort to educate the lawmakers and the public, events like this will be able to open the eyes of those who have willfully ignored the issue.

    NORML chapters throughout the country are working to advance legalization in state legislatures and, with your support, National NORML will continue to up the pressure in Washington, DC.

    Click here to share the video through your networks and support efforts like this in the future. 

     

Page 3 of 41234